alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit
35.1







Servicer
Compliance Statement of AmeriCredit Financial Services, Inc.



This Annual Statement as to Compliance is delivered to you pursuant to Section 2.9 (c) of the 2018-2 Servicing
Supplement dated as of April 30, 2018 (the “Agreement”) and Item 1123 of Regulation AB, executed in connection with
the formation of GM Financial Automobile Leasing Trust 2018-2 (the “Trust”), the issuance of the Notes by the Trust
and the closing of the transactions and the execution and delivery of the various documents by AmeriCredit Financial Services,
Inc. (the “Servicer”) and GMF Leasing LLC in connection therewith. The capitalized terms used herein shall have the
same meanings as in the Agreement.



The
undersigned certifies that I am the Executive Vice President, Corporate Controller and Chief Accounting Officer of the Servicer.
I further certify as follows:



| | 1. | I have conducted, or caused to be conducted under my supervision, a review of the Servicer during the
preceding period from April 30, 2018 through December 31, 2018, and its performance under the Agreement.
| | -- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 2. | To
                                         the best of my knowledge, following such review, the Servicer has fulfilled all its obligations
                                         under the Agreement throughout such period, and, to the best of my knowledge, there has
                                         been no default in the fulfillment of any such obligation.
| | -- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------





|                                         |                                             |  |                     
|---------------------------------------- | ------------------------------------------- |  | --------------------
|AmeriCredit Financial
    Services, Inc. |                                             | 
|                                         |                                             |  |                     
|By:                                      | /s/
    Connie Coffey                       |  | Dated: March 8, 2019
|                                         | Connie Coffey                               |  |                     
|                                         | Executive Vice President, Corporate         |  |                     
|                                         | Controller and Chief Accounting
    Officer |  |
**Exhibit 31.2** **CERTIFICATION    OF PRINCIPAL FINANCIAL OFFICER****PURSUANT TO SECTION 302****OF THE SARBANES-OXLEY ACT OF 2002**     I, Curtis J. Larrimer, certify that:     1. I have reviewed this    Form 10-Q    of GNC Corporation;     2. Based on my knowledge, this report does not contain any    untrue statement of a material fact or omit to state a material    fact necessary to make the statements made, in light of the    circumstances under which such statements were made, not    misleading with respect to the period covered by this report;     3. Based on my knowledge, the financial statements, and    other financial information included in this report, fairly    present in all material respects the financial condition,    results of operations and cash flows of the registrant as of,    and for, the periods presented in this report;     4. The registrant’s other certifying officer(s) and I    are responsible for establishing and maintaining disclosure    controls and procedures (as defined in Exchange Act    Rules 13a-15(e)    and    15d-15(e))    for the registrant and have:     (a) Designed such disclosure controls and procedures, or    caused such disclosure controls and procedures to be designed    under our supervision, to ensure that material information    relating to the registrant, including its consolidated    subsidiaries, is made known to us by others within those    entities, particularly during the period in which this report is    being prepared;     (b) Evaluated the effectiveness of the registrant’s    disclosure controls and procedures and presented in this report    our conclusions about the effectiveness of the disclosure    controls and procedures, as of the end of the period covered by    this report based on such evaluation; and     (c) Disclosed in this report any change in the    registrant’s internal control over financial reporting that    occurred during the registrant’s most recent fiscal quarter    (the registrant’s fourth fiscal quarter in the case of an    annual report) that has materially affected, or is reasonably    likely to materially affect, the registrant’s internal    control over financial reporting; and     5. The registrant’s other certifying officer(s) and I    have disclosed, based on our most recent evaluation of internal    control over financial reporting, to the registrant’s    auditors and the audit committee of the registrant’s board    of directors (or persons performing the equivalent functions):     (a) All significant deficiencies and material weaknesses in    the design or operation of internal control over financial    reporting which are reasonably likely to adversely affect the    registrant’s ability to record, process, summarize, and    report financial information; and     (b) Any fraud, whether or not material, that involves    management or other employees who have a significant role in the    registrant’s internal control over financial reporting. /s/  Curtis    J. Larrimer    Curtis J. Larrimer    Chief Financial Officer     August 4, 2006
**Exhibit 23.1****Consent of Independent Registered Public Accounting Firm**     We consent to the incorporation by reference in the Registration Statements on Form S-8(Registration Nos. 333-123332, 333-58648, 333-59826, 333-82122, 333-104697 and 333-113299) and Form S-3 (Registration Nos. 333-10779, 333-107028 and 333-129687) of ourreports dated March 10, 2006, with respect to the consolidated financial statements of IntrogenTherapeutics, Inc., Introgen Therapeutics, Inc. management’s assessment of the effectiveness ofinternal control over financial reporting, and the effectiveness of internal control over financialreporting of Introgen Therapeutics, Inc., included in the Annual Report (Form 10-K) for the fiscalyear ended December 31, 2005, as amended by this Annual Report (Form 10-K/A) for the fiscal year ended December 31, 2005./s/ Ernst & Young LLPAustin, Texas
Exhibit 32.2



Certification pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley act of 2001.



In connection with the Quarterly Report of AT&S Holdings, Inc. (the "Company") on Form 10-QSB for the period ended September 30, 2004, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Richard G. Honan II, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2001,

that:



·

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



·

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.





Dated:  November 18, 2004



/s/ Richard G. Honan II

------------------------

Richard G. Honan II

Chief Financial Officer
I 

110TH CONGRESS 

2D SESSION H. R. 4953 

To extend the duty suspension on 1-Fluoro-2-nitrobenzene. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 15, 2008 

Mr. DAVID DAVIS of Tennessee introduced the following bill; which was 

referred to the Committee on Ways and Means 

A BILL 

To extend the duty suspension on 1-Fluoro-2-nitrobenzene. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. 1-FLUORO-2-NITROBENZENE. 

4 (a) IN GENERAL.—Heading 9902.11.37 of the Har5 monized Tariff Schedule of the United States (relating to 

6 1-Fluoro-2-nitrobenzene) is amended by striking ‘‘12/31/ 

7 2009’’ and inserting ‘‘12/31/2011’’. 

8 (b) EFFECTIVE DATE.—The amendment made by 

9 subsection (a) applies with respect to goods entered, or 

10 withdrawn from warehouse for consumption, on or after 


ccoleman on PRODPC75 with BILLS
2 

•HR 4953 IH

1 the date that is 15 days after the date of enactment of 

2 this Act. 

Æ 


ccoleman on PRODPC75 with BILLS
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the Keebler
Foods Company Consolidated Balance Sheet at January 3, 1998 and the Consolidated
Statement of Operations for the year ended January 3, 1998 found on pages F-3
through F-5 of the Company's Form 10-K and is qualified in its entirety by
reference to such financial statements.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          JAN-03-1998
<PERIOD-START>                             DEC-29-1996
<PERIOD-END>                               JAN-03-1998
<CASH>                                          27,188
<SECURITIES>                                         0
<RECEIVABLES>                                  103,928
<ALLOWANCES>                                     4,965
<INVENTORY>                                    112,462
<CURRENT-ASSETS>                               301,646
<PP&E>                                         576,786
<DEPRECIATION>                                  98,665
<TOTAL-ASSETS>                               1,042,851
<CURRENT-LIABILITIES>                          368,185
<BONDS>                                        272,390
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           776
<OTHER-SE>                                     221,275
<TOTAL-LIABILITY-AND-EQUITY>                 1,042,851
<SALES>                                      2,065,184
<TOTAL-REVENUES>                             2,065,184
<CGS>                                          888,031
<TOTAL-COSTS>                                1,914,276
<OTHER-EXPENSES>                                 9,511
<LOSS-PROVISION>                                18,970
<INTEREST-EXPENSE>                              33,847
<INCOME-PRETAX>                                107,550
<INCOME-TAX>                                    45,169
<INCOME-CONTINUING>                             62,381
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                (5,396)
<CHANGES>                                            0
<NET-INCOME>                                    56,985
<EPS-PRIMARY>                                     0.73
<EPS-DILUTED>                                     0.70
        

</TABLE>
---

Exhibit 13.a CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report on Form 20-F for the year ended December 31, 2010 of Nymox Pharmaceutical Corporation and filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Nymox Pharmaceutical Corporation. Date: June 3, 2011/s/ Paul Averback, MDPaul Averback, MDPresident and Chief Executive OfficerNymox Pharmaceutical Corporation


---
STATE v. EVANS

No. COA03-1693.

Court of Appeals of North Carolina.

Filed March 1, 2005.

Certification Date March 21, 2005.

Case reported without published opinion. No error.
IN RE J.L.R.

No. COA04-728.

Court of Appeals of North Carolina.

Filed March 15, 2005.

Certification Date April 4, 2005.

Appeal from the Davidson (02J117).

Case reported without published opinion. Affirmed.
<PAGE>

                                                                      EXHIBIT 24

                                 POWER OF ATTORNEY

  We, the undersigned officers and directors of Viisage Technology, Inc., hereby
jointly and severally constitute and appoint Thomas J. Colatosti and Charles J.
Johnson, and each of them singly, our true and lawful attorneys with full power
to them, and each of them singly, to sign for us and in our names in the
capacities indicated below, the Annual Report on Form 10-K filed herewith and
any and all amendments to said Registration Statement and generally to do all
such things in our names and on our behalf in our capacities as officers and
directors to enable Viisage Technology, Inc. to comply with the Securities Act
of 1934, as amended, and all requirements of the Securities and Exchange
Commission, hereby ratifying and confirming all signatures as they may be signed
by our said attorneys, or any of them, to said Registration Statement and all
amendments thereto.

Signature          Title
---------          -----

By: /s/ Denis K. Berube            Chairman of the Board of Directors
    -------------------
Denis K. Berube


By: /s/ Thomas J. Colatosti        President and Chief Executive Officer
    -----------------------
Thomas J. Colatosti                (Principal Executive Officer and Principal
                                    Financial and Accounting Officer)


By: /s/ Charles J. Johnson         Secretary and Director
    ----------------------
Charles J. Johnson


By: /s/ Harriet Mouchly-Weiss      Director
    -------------------------
Harriet Mouchly-Weiss


By: /s/ Peter Nessen               Director
    ----------------
Peter Nessen


By: /s/ Thomas J. Reilly           Director
    --------------------
Thomas J. Reilly


By:  /s/ Charles E. Levine         Director
     ---------------------
Charles E. Levine
# CA2007116EN.01000101.xml

| 26.5.2007 | EN | Official Journal of the European Union | CA 116/1 |
| --- | --- | --- | --- |

26.5.2007

EN

Official Journal of the European Union

CA 116/1

---

NOTICE TO READERS

Image

---
EXHIBIT
32







CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002





In
connection with the Quarterly Report of Premier Alliance Group, Inc., a Nevada
corporation (the "Company") on Form 10-Q for the period ended March 31, 2010, as
filed with the Securities and Exchange Commission on the date hereof (the
"Report"), Mark S. Elliott, Acting Chief Executive and Financial Officer of the
Company, certifies to the best of his knowledge, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that:





(1)
            The
      Report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934; and(2)
            The
      information contained in the Report fairly presents, in all material
      respects, the financial condition and result of operations of the
      Company.





A signed
original of this written statement required by Section 906 has been provided to
Premier Alliance Group, Inc., and will be retained by Premier Alliance Group,
Inc. and furnished to the Securities and Exchange Commission or its staff upon
request.








/s/ Mark S. Elliott


Mark S.
Elliott


Acting
Chief Executive and Financial
Officer


May 14,
2010
1. Home
2. Facts
3. What is a mangrove forest?

**What is a mangrove forest?**  Mangroves are a group of **trees and shrubs** that live in the **coastal intertidal zone**. A Floridian Mangrove forest
    				Mangrove forest in Loxahatchee, Florida.  There are about 80 different species of mangrove trees. All  of these trees grow in areas with low-oxygen soil, where slow-moving waters  allow fine sediments to accumulate. Mangrove forests only grow at tropical and  subtropical latitudes near the equator because they cannot withstand freezing  temperatures. Many mangrove forests can be recognized by their dense  tangle of prop roots that make the trees appear to be standing on stilts above  the water. This tangle of roots allows the trees to handle the daily rise and  fall of tides, which means that most mangroves get flooded at least twice per  day. The roots also slow the movement of  tidal waters, causing sediments to settle out of the water and build up the  muddy bottom. Mangrove forests stabilize  the coastline, reducing erosion from storm surges, currents, waves, and tides. The intricate root system of mangroves also makes these forests attractive to  fish and other organisms seeking food and shelter from predators.
  More **Information** Coastal Blue Carbon   **Search** Our facts    Get **Social** Social
  **Last updated:** 01/20/23 **Author:** NOAA How to cite this article Contact Us


Feedback Provide Feedback
							Contact Us
							Report an error
 Social Instagram Logo/a>


*Science. Service.Stewardship.*
 About NOS About Us
							NOS Program Offices
							Media Inquiries
							Website Acknowledgements
                            Site Index
							Disclaimer
 More Resources Freedom of Information Act
							Accessibility
							Information Quality
							Privacy Policy
							NOS For Employees
							USA.gov
 Department of Commerce
									National Oceanic and Atmospheric Administration (NOAA)
									National Ocean Service
EXHIBIT 32.1




CERTIFICATION PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002




In connection with the Quarterly Report of New York Mortgage Trust, Inc, (the “Company”) on Form 10-Q for the quarter ended June 30, 2009, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies, pursuant to 18 U.S.C. §
1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:




(1)           The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and




(2)           The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.







Date: August 7, 2009

/s/ Steven R. MummaSteven R. Mumma
Chief Executive Officer and Chief Financial Officer
(Principal Executive and Principal Financial Officer)
ROBESON COUNTY DSS EX REL. BLACK v. McGEACHY.

No. COA04-1305.

Court of Appeals of North Carolina.

Filed July 5, 2005.

Certification Date July 25, 2005.

Appeal from the Robeson (98CVD1569).

Case without published opinion. No error.
EXHIBIT 31.1

                OFFICER'S CERTIFICATION PURSUANT TO SECTION 302

I,  Caroline  Rechia,  the  President,  Chief Executive Officer, Chief Financial
Officer  and  Principal  Accounting  Officer of PortaltoChina.com, Inc., certify
that:

1.     I  have reviewed this quarterly report on Form 10-Q of PortaltoChina.com,
Inc.;

2.     Based  on my knowledge, this report does not contain any untrue statement
of  a  material  fact  or  omit  to  state a material fact necessary to make the
statements  made, in light of the circumstances under which such statements were
made,  not  misleading  with  respect  to  the  period  covered  by this report;

3.     Based  on  my  knowledge,  the  financial statements, and other financial
information included in this report, fairly present in all material respects the
financial  condition, results of operations and cash flows of the small business
issuer  as  of,  and  for,  the  periods  presented  in  this  report;

4.     I am responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the
registrant and I have:

a)     designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to me by others within those entities, particularly during the
period in which this quarterly report is being prepared;

b)     evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

c)     presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on my evaluation
as of the Evaluation Date;

5.     I have disclosed, based on our most recent evaluation, to the
registrant's auditors and the audit committee of registrant's board of directors
(or persons performing the equivalent function):

a)     all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and

b)     any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls.

6.     I have indicated in this quarterly report whether there were significant
changes in internal controls or in other factors that could significantly affect
internal controls subsequent to the date of my most recent evaluation, including
any corrective actions with regard to significant deficiencies and material
weaknesses.

April  10,  2009


By /s/ Caroline Rechia
Caroline Rechia
President, Chief Executive Officer,
Chief Financial Officer and
Principal Accounting Officer
Exhibit 21.1



SUBSIDIARIES



Information relating to the subsidiaries of QuadraMed as of January 1, 2005 is set forth below. All of the indicated subsidiaries are directly or
indirectly wholly-owned by QuadraMed except as indicated.



|                                         |  |                                              
|---------------------------------------- |  | ---------------------------------------------
|Name of Subsidiary                       |  | Jurisdiction of Incorporation or Organization
|QuadraMed Financial Services Corporation |  | California                                   
|                                         | 
|QuadraMed Affinity Corporation           |  | Delaware                                     
|                                         | 
|Tempus Software LLC                      |  | Delaware                                     
|                                         | 
|QuadraMed International Pty Limited      |  | Australia                                    
|                                         | 
|QuadraMed International Limited          |  | United Kingdom